Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Journey Travel Objections for Your Next Experience - 2The most effective method to Recuperate After a Dental Embed Strategy: A Far reaching Guide
- 3You finally got a doctor's appointment. Here's how to get the most out of it
- 4What we know about Renee Nicole Good, the woman who was killed by an ICE officer in Minneapolis
- 5Exploring the Gig Economy: Illustrations from Consultants
- Far-right German youth group delegates seek deportations, remigration
- Turkey key underlying issue as Israel, Greece, Cyprus hold summit
- Figure out How to Reveal Stowed away Open Record Rewards
- How the Iran war may affect your money and bills
- Gauging the Upsides and downsides of Visas: A Complete Aide
- Experience Is standing by: 10 Pleasant Setting up camp Areas to
- Merck sees over $5 billion opportunity in Cidara's experimental flu drug
- Step by step instructions to Pick the Right Dental specialist for Your Dental Inserts Technique
- How does Spotify Wrapped calculate your listening age? What your number says about you.
